publicationMetadata:
  pmid: "37410426"
  title: "CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression"
  queryType: "unknown"  # Not provided in input
  publicationType: "Lab Research"
  publicationTypeConfidence: 0.95
  hasMethodsSection: Yes
  likelyContainsTools: Yes
  expectedToolTypes: |
    This is a preclinical cancer research study that should contain multiple tool types:
    - Patient-derived xenografts (PDX models) - explicitly mentioned
    - Animal models (de novo mouse MPNSTs) - explicitly mentioned  
    - Cell lines (MPNST cell lines) - explicitly mentioned
    - Computational tools (RNA sequencing, Connectivity-Map analyses) - mentioned
    - Potentially antibodies for IHC and flow cytometry
    - Genetic reagents for creating mouse models
    
    This publication spans both lab research tools and patient-derived models, making it a comprehensive
    preclinical study that should have yielded multiple validated research tools.
  overallAssessment: |
    This is a comprehensive preclinical cancer research study that extensively uses research tools including
    patient-derived xenografts, mouse models, cell lines, and computational analysis methods. The study
    describes experimental procedures using these tools to test drug combinations and immune responses.
    The complete absence of mined tools represents a major failure in the mining process, as this publication
    clearly contains multiple categories of research tools that are central to the experimental design.

toolValidations: []  # No tools were mined to validate

potentiallyMissedTools:
  - toolName: "patient-derived xenografts"
    toolType: "patient_derived_model"
    foundIn: "abstract"
    contextSnippet: "Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs"
    whyMissed: "Standard PDX terminology should have been detected by patient-derived model patterns"
    confidence: 0.98
    shouldBeAdded: Yes

  - toolName: "PDX"
    toolType: "patient_derived_model"
    foundIn: "abstract"
    contextSnippet: "dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs"
    whyMissed: "PDX abbreviation is standard terminology for patient-derived xenografts"
    confidence: 0.98
    shouldBeAdded: Yes

  - toolName: "MPNST cell lines"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX)"
    whyMissed: "Cell line terminology with disease context should have been detected"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "de novo mouse MPNSTs"
    toolType: "animal_model"
    foundIn: "abstract"
    contextSnippet: "measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs, with the latter used to determine anti-PD-L1 response"
    whyMissed: "Mouse model terminology should have been detected by animal model patterns"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "RNA sequencing"
    toolType: "computational_tool"
    foundIn: "abstract"
    contextSnippet: "Patient-matched MPNSTs and precursor lesions were examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses"
    whyMissed: "RNA sequencing is a standard computational analysis method"
    confidence: 0.90
    shouldBeAdded: Yes

  - toolName: "RNAseq"
    toolType: "computational_tool"
    foundIn: "methods"
    contextSnippet: "Patient-matched MPNSTs and precursor lesions were examined by FISH, RNAseq, IHC, and Connectivity-Map analyses"
    whyMissed: "RNAseq abbreviation is standard terminology for RNA sequencing"
    confidence: 0.90
    shouldBeAdded: Yes

  - toolName: "Connectivity-Map"
    toolType: "computational_tool"
    foundIn: "abstract"
    contextSnippet: "examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses"
    whyMissed: "Connectivity Map (CMap) is a well-known computational tool for drug discovery"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "immunocompetent mice"
    toolType: "animal_model"
    foundIn: "results"
    contextSnippet: "In immunocompetent mice, combination therapy of de novo MPNSTs caused tumor regression"
    whyMissed: "Specific mouse strain/type terminology should be detected"
    confidence: 0.80
    shouldBeAdded: Yes

  - toolName: "immune-deficient mice"
    toolType: "animal_model"
    foundIn: "results"
    contextSnippet: "In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs"
    whyMissed: "Specific mouse strain/type terminology should be detected"
    confidence: 0.80
    shouldBeAdded: Yes

suggestedPatterns:
  - patternType: "term"
    pattern: "patient-derived xenograft[s]?"
    toolType: "patient_derived_model"
    examples: ["patient-derived xenografts (PDX)"]
    reasoning: "Standard terminology for PDX models that should always be detected"

  - patternType: "term"
    pattern: "PDX[s]?"
    toolType: "patient_derived_model"
    examples: ["4 of 5 MPNST PDXs"]
    reasoning: "Common abbreviation for patient-derived xenografts"

  - patternType: "context_phrase"
    pattern: "\\b\\w+\\s+cell lines?"
    toolType: "cell_line"
    examples: ["MPNST cell lines"]
    reasoning: "Disease/tissue-specific cell lines are commonly named this way"

  - patternType: "context_phrase"
    pattern: "de novo\\s+mouse\\s+\\w+"
    toolType: "animal_model"
    examples: ["de novo mouse MPNSTs"]
    reasoning: "De novo mouse models are standard terminology in cancer research"

  - patternType: "term"
    pattern: "RNA\\s*sequencing|RNAseq|RNA-seq"
    toolType: "computational_tool"
    examples: ["RNA sequencing", "RNAseq"]
    reasoning: "Standard computational analysis method with multiple naming conventions"

  - patternType: "term"
    pattern: "Connectivity[\\s-]?Map|CMap"
    toolType: "computational_tool"
    examples: ["Connectivity-Map analyses"]
    reasoning: "Well-known computational drug discovery tool"

  - patternType: "context_phrase"
    pattern: "immune[\\s-]?deficient\\s+mice|immunocompetent\\s+mice"
    toolType: "animal_model"
    examples: ["immune-deficient mice", "immunocompetent mice"]
    reasoning: "Specific mouse strain types commonly used in cancer research"

  - patternType: "context_phrase"
    pattern: "measured in\\s+[^,]+cell lines?|activity.*in\\s+[^,]+cell lines?"
    toolType: "cell_line"
    examples: ["measured in MPNST cell lines"]
    reasoning: "Context phrases indicating experimental use of cell lines"

  - patternType: "context_phrase"
    pattern: "examined by\\s+[^,]*(?:FISH|IHC|sequencing|analyses)"
    toolType: "computational_tool"
    examples: ["examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses"]
    reasoning: "Context indicating use of analytical/computational methods"

observations:
  - resourceName: "patient-derived xenografts"
    resourceType: "Patient-Derived Model"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      Dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs in immune-deficient mice.
      This represents an 80% response rate to the combination therapy, indicating significant antitumor
      activity across multiple patient-derived models.
    foundIn: "results"
    contextSnippet: "In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs"
    confidence: 0.95
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

  - resourceName: "de novo mouse MPNSTs"
    resourceType: "Animal Model"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      In immunocompetent mice, combination CDK4/6-MEK therapy caused tumor regression and delayed
      resistant tumor outgrowth compared to monotherapies. Some mice showed complete tumor regression
      when combined with anti-PD-L1 immune checkpoint blockade.
    foundIn: "results"
    contextSnippet: "combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies"
    confidence: 0.95
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

  - resourceName: "de novo mouse MPNSTs"
    resourceType: "Animal Model"
    observationType: "Lifespan"
    observationTypeOntologyId: "MP:0001262"
    details: |
      Combination CDK4/6-MEK therapy improved survival relative to monotherapies in mice with
      de novo MPNSTs. This survival benefit was associated with tumor regression and delayed
      development of drug resistance.
    foundIn: "results"
    contextSnippet: "combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies"
    confidence: 0.90
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

  - resourceName: "MPNST cell lines"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1)
      tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells. This demonstrates
      the cellular mechanism of action for the drug combination.
    foundIn: "results"
    contextSnippet: "Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1) tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells"
    confidence: 0.95
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

  - resourceName: "de novo mouse MPNSTs"
    resourceType: "Animal Model"
    observationType: "Immune System"
    observationTypeOntologyId: "MP:0005387"
    details: |
      Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells,
      whereas drug-resistant tumors adopted an immunosuppressive microenvironment with elevated
      MHC II-low macrophages and increased tumor cell PD-L1 expression. This reveals distinct
      immune microenvironment changes associated with drug sensitivity.
    foundIn: "results"
    contextSnippet: "Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells, whereas drug-resistant tumors adopted an immunosuppressive microenvironment"
    confidence: 0.90
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

  - resourceName: "RNA sequencing"
    resourceType: "Computational Tool"
    observationType: "Usage Instructions"
    observationTypeOntologyId: ""
    details: |
      RNA sequencing was used along with FISH, IHC, and Connectivity-Map analyses to examine
      patient-matched MPNSTs and precursor lesions to identify CDK4/6 and MEK as actionable
      targets for MPNST therapy.
    foundIn: "results"
    contextSnippet: "Patient tumor analyses identified CDK4/6 and MEK as actionable targets for MPNST therapy"
    confidence: 0.85
    doi: "https://doi.org/10.1158/1078-0432.CCR-23-0749"

summary:
  totalToolsMined: 0
  toolsAccepted: 0
  toolsRejected: 0
  toolsUncertain: 0
  potentiallyMissedCount: 9
  newPatternsCount: 9
  observationsExtracted: 6
  observationsByType:
    Tumor Growth: 2
    Lifespan: 1
    Cellular: 1
    Immune System: 1
    Usage Instructions: 1
  majorIssuesFound: |
    - CRITICAL: Complete mining failure - zero tools detected despite clear evidence of multiple research tools
    - Publication contains patient-derived xenografts (PDX), cell lines, animal models, and computational tools
    - Standard terminology like "PDX", "cell lines", "RNA sequencing" was not detected
    - This represents a systematic failure of the mining patterns to detect common research tools
    - All major tool categories present in this preclinical study were missed
  recommendations: |
    This publication represents a complete mining failure that requires immediate attention:
    
    1. URGENT: Review and update mining patterns - basic terms like "PDX", "cell lines", "RNA sequencing" should never be missed
    2. Add all 9 identified tools to the database as they represent clear, validated research tools
    3. Implement the 9 suggested patterns to prevent similar failures in future mining
    4. This publication should be used as a test case to validate improved mining algorithms
    5. Consider manual review of other publications from the same mining run to assess scope of the problem
    6. The 6 extracted observations provide valuable scientific insights about these research tools
    
    The complete absence of detected tools in a publication that extensively uses research tools indicates
    fundamental issues with the current mining approach that need immediate correction.
